GHRP-2
Growth Hormone Releasing Peptide-2
GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a potent agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R). It triggers pulsatile growth hormone release from the pituitary gland, mimicking the body's natural GH secretion patterns. GHRP-2 was developed as a diagnostic agent and is clinically approved in Japan for assessing growth hormone deficiency. Unlike direct GH administration, GHRP-2 works through the body's natural pathways, making it a preferred option for those seeking to enhance their natural growth hormone production safely and effectively.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.